That was the methodology for the research. The paper shows that specifc types of chemotherapy related damage can trigger desirable immunological responses, so I'd guess the end
goal would be a regular chemotherapy regimen that trigger that response. The end of the abstract hints at that by saying the research provides a strategy for increased efficacy, rather than claiming to be a potential treatment or adjuvant.
